LATIN AMERICA

We have an established history of more than 10 years in Latin America. Mexico and Brazil account for almost 80% of the revenue generated in the region. Our expanded regional coverage gives us a presence Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina. Our comprehensive product range encompasses in branded prescription and OTC products.

Key Countries

Brazil
Chile
Colombia
Ecuador
Mexico

Contribution to Group revenue (%)

Revenue by segment (%)

The Spanish Latin American private pharmaceutical sector grew 4.3% in value for the year to 31 August 2019 as compared to the prior period
The Brazilian private pharmaceutical market declined 7% and was valued by IMS at USD28 billion for the year to 30 June 2019, negatively impacted by foreign exchange

Source: June 2019 IQVIA

STATISTICS

Number of products launched:

8

(2018: 6)^#

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD426 million

3 – 5 years

USD493 million

Number of product recalls:

Nil

(2018: 2)

Average staff turnover*:

24,9%

(2018: 22,8%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

^# The number of product launches has been restated to take into account discontinued operations.
^ Includes 468 employees transferred with the disposal of the Nutritionals business.
* Rate excludes employees transferred in Nutritionals disposal.

Revenue	2019 R'million	2018 (CER) R'million	change %
Regional Brands	2 114	2 001	6
Sterile Focus Brands	969	909	7
Anaesthetics Brands	894	835	7
Thrombosis Brands	75	74	1
Total	3 083	2 910	6

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.